Browsing Clinical Studies by author "Jones, Robin"
Now showing items 41-54 of 54
-
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113).
Ray-Coquard, I; Hatcher, H; Bompas, E; Casado, A; Westermann, A; et al. (BMJ PUBLISHING GROUP, 2020-10-01)BACKGROUND: Uterine sarcomas are a group of rare tumors that include different subtypes. Patients with histopathological high-grade diseases are at high-risk of recurrence or progression, and have a poor prognosis. We aim ... -
Rare Aggressive Behavior of <i>MDM2</i>-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases.
Ben Salha, I; Zaidi, S; Noujaim, J; Miah, AB; Fisher, C; et al. (2016-09)Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, non-lipogenic sarcoma. It can occur as part of ... -
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri, A; Smith, IE; Hills, M; Jones, RL; Johnston, SR; et al. (2017-07)Aims To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 ... -
A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.
Bui, N; Dietz, H; Farag, S; Hirbe, AC; Wagner, MJ; et al. (MDPI, 2023-05-05)BACKGROUND: Dedifferentiated chondrosarcoma (DDCS) is a rare subset of chondrosarcoma. It is an aggressive neoplasm characterized by a high rate of recurrent and metastatic disease with overall poor outcomes. Systemic ... -
Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan, A; Kucharczyk, MA; Jones, RL; Constantinidou, A (TAYLOR & FRANCIS LTD, 2023-02-01)INTRODUCTION: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate revolutionized the management of advanced/metastatic GIST, and remains the standard ... -
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer, S; Jones, RL; Blay, J-Y; Gelderblom, H; George, S; et al. (American Society of Clinical Oncology (ASCO), 2022-08-10)PURPOSE: Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after ... -
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder, MM; Razak, AA; Somaiah, N; Chawla, S; Martin-Broto, J; et al. (American Society of Clinical Oncology (ASCO), 2022-04-08)PURPOSE: Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with ... -
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma.
Smrke, A; Thway, K; H Huang, P; Jones, RL; Hayes, AJ (FUTURE MEDICINE LTD, 2021-09-01)Solitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has ... -
Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management.
Owen, C; Constantinidou, A; Miah, AB; Thway, K; Fisher, C; et al. (2018-09)Background/aim Synovial sarcoma is a soft tissue sarcoma that tends to affect young adults. There are few reports on primary synovial sarcoma of the thyroid and the aim of this study was to document the clinical and ... -
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
Frezza, AM; Ravi, V; Lo Vullo, S; Vincenzi, B; Tolomeo, F; et al.Background This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra-rare sarcoma, marked by WWTR1-CAMTA1 or YAP1-TFE3 fusions.Methods ... -
The evolving management of epithelioid sarcoma.
Alves, A; Constantinidou, A; Thway, K; Fisher, C; Huang, P; et al. (2021-07-18) -
The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities.
Noujaim, J; Jones, RL; Swansbury, J; Gonzalez, D; Benson, C; et al. (2017-02)Background EWSR1 rearrangements were first identified in Ewing sarcoma, but the spectrum of EWSR1-rearranged neoplasms now includes many soft tissue tumour subtypes including desmoplastic small round cell tumour (DSRCT), ... -
A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors.
Gennatas, S; Chamberlain, F; Smrke, A; Stewart, J; Hayes, A; et al. (WILEY, 2020-10-02)INTRODUCTION: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent ... -
What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland.
McCabe, HM; Smrke, A; Cowie, F; White, J; Chong, P; et al.Purpose In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care. The COVID-19 ...